DexCom DXCM
DexCom is a medical device company that develops and sells continuous glucose monitoring (CGM) systems for people with diabetes, generating recurring revenue from sensors and consumables. DexCom combines exceptional quality (ROE 38.49%, ROIC 30.07%) with solid growth (revenue +13.1%, earnings +43.6%) and a net cash balance sheet, but its demanding valuation (P/E 34.24) and the rise in 10-year yields limit near-term appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
DexCom is a medical device company that develops and sells continuous glucose monitoring (CGM) systems for people with diabetes, generating recurring revenue from sensors and consumables. DexCom combines exceptional quality (ROE 38.49%, ROIC 30.07%) with solid growth (revenue +13.1%, earnings +43.6%) and a net cash balance sheet, but its demanding valuation (P/E 34.24) and the rise in 10-year yields limit near-term appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.2 |
| Quality / Moat | 8.9 |
| Valuation | 3.7 |
| Growth | 8.1 |
| Dividend | 1.5 |
| Momentum | 8.5 |
| Risk & Context | 4.0 |
OVERALL SCORE: 6.4/10
Context and risks
The rise in 10-year Treasury yields (5.17%) affects DexCom's valuation due to its high P/E (34.24) and long-duration growth profile, but its net cash balance sheet limits the impact on financial health. The effect is moderate and partially priced in.
News considered in the analysis
- DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer — Promoción interna de un ejecutivo con profundo conocimiento de la empresa; señal de continuidad operativa, impacto moderado y positivo.
- Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced? — Artículo de análisis sin información nueva; no aporta hechos materiales.
- DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow — Opinión de valoración sin catalizador concreto; ruido.
- 2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds — Listículo genérico sin información específica sobre DexCom.
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring — Noticia sobre un competidor indirecto en salud de consumo; sin impacto directo en el negocio de CGM de DexCom.
Verdict: Hold; quality and growth justify the premium, but the current multiple and high-rate environment offer no margin of safety.
Main risk: The demanding valuation (P/E 34.24) is vulnerable to multiple compression if rates keep rising or growth decelerates.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →